Relapsing-remitting Multiple Sclerosis
126
3
7
89
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
37 trials with published results (29%)
Research Maturity
89 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
14.3%
18 terminated out of 126 trials
83.2%
-3.3% vs benchmark
37%
46 trials in Phase 3/4
42%
37 of 89 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 89 completed trials
Clinical Trials (126)
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The HIt HArd and hiT Early in Multiple Sclerosis Trial
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
COMparison Between All immunoTherapies for Multiple Sclerosis.
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a